Investing.com -- Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company’s announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during GLP-1 therapy in combination with the Allurion Program.
The significant rise in the company’s stock price can be attributed to the promising potential of the Allurion Program to address the reductions in lean mass often seen with GLP-1 therapy, a prevalent issue in obesity treatment. According to the press release, prior studies have shown that patients on GLP-1 therapy tend to lose about 40% of lean mass as a proportion of total weight lost. In contrast, patients treated with the Allurion Balloon and Allurion Virtual Care Suite have not only lost weight but have also maintained or even gained lean body mass.
The CEO of Allurion, Dr. Shantanu Gaur, expressed optimism about the upcoming clinical study, stating that the company’s early data suggests they may have a significant tool for achieving metabolically healthy weight loss. Dr. Gaur highlighted the potential for the combination therapy to become the gold standard in obesity care if the study confirms the preliminary findings.
Allurion Technologies is focused on ending obesity through its innovative weight-loss platform, which includes the Allurion Gastric Balloon, the first swallowable, procedure-less gastric balloon for weight loss, and a comprehensive virtual care suite. The virtual care offering is designed to support healthcare providers in customizing and managing weight-loss therapy for patients, regardless of the treatment plan they are on.
Investors are closely monitoring the developments of Allurion’s clinical study, as positive results could significantly impact the obesity treatment market. The company’s approach to preserving muscle mass while promoting weight loss presents a potentially transformative solution in the field of weight management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.